BR112015028516A2 - tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina - Google Patents

tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina

Info

Publication number
BR112015028516A2
BR112015028516A2 BR112015028516A BR112015028516A BR112015028516A2 BR 112015028516 A2 BR112015028516 A2 BR 112015028516A2 BR 112015028516 A BR112015028516 A BR 112015028516A BR 112015028516 A BR112015028516 A BR 112015028516A BR 112015028516 A2 BR112015028516 A2 BR 112015028516A2
Authority
BR
Brazil
Prior art keywords
neurodegenerative disorders
iciline
menthol
prevention
treatment
Prior art date
Application number
BR112015028516A
Other languages
English (en)
Portuguese (pt)
Inventor
Markram Henry
Le Coutre Johannes
Pezzoli Maurizio
Michlig Gonzalez Stéphanie
Camacho Susana
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015028516A2 publication Critical patent/BR112015028516A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015028516A 2013-05-24 2014-05-23 tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina BR112015028516A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827243P 2013-05-24 2013-05-24
PCT/EP2014/060632 WO2014187942A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin

Publications (1)

Publication Number Publication Date
BR112015028516A2 true BR112015028516A2 (pt) 2017-07-25

Family

ID=50819727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028516A BR112015028516A2 (pt) 2013-05-24 2014-05-23 tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina

Country Status (8)

Country Link
US (1) US20160108004A1 (cg-RX-API-DMAC7.html)
EP (1) EP3003291A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016524608A (cg-RX-API-DMAC7.html)
CN (1) CN105228602A (cg-RX-API-DMAC7.html)
AU (1) AU2014270338A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015028516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2908402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014187942A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800751T3 (es) 2016-02-22 2021-01-04 Newtricious Bv Composición para la prevención o tratamiento de enfermedades neurodegenerativas
JP7225103B2 (ja) 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ,インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
CN109674851A (zh) * 2017-10-18 2019-04-26 大江生医股份有限公司 薄荷精油的应用
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
JP7641973B2 (ja) * 2020-03-24 2025-03-07 中国▲医▼薬大学 神経変性疾患及び脳卒中を改善する外用組成物の調製に用いられるメントールの用途
JP7194484B2 (ja) * 2020-10-21 2022-12-22 三井農林株式会社 脳機能改善剤
CN116919930A (zh) * 2022-04-06 2023-10-24 沈阳药科大学 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007302572A (ja) * 2006-05-09 2007-11-22 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
JP2008231049A (ja) * 2007-03-22 2008-10-02 Saburo Yasuda アポトーシス誘導物質
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
JP5738755B2 (ja) * 2008-05-09 2015-06-24 アイカーン スクール オブ メディシン アット マウント シナイ 神経変性疾患を予防および治療するための方法
KR101189763B1 (ko) * 2010-06-10 2012-10-10 고려대학교 산학협력단 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
WO2013168090A1 (en) * 2012-05-07 2013-11-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Researc Organization (Aro) (Volcanii Center). Geranium oil and constituents thereof for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20160108004A1 (en) 2016-04-21
WO2014187942A1 (en) 2014-11-27
AU2014270338A1 (en) 2015-10-08
CN105228602A (zh) 2016-01-06
JP2016524608A (ja) 2016-08-18
CA2908402A1 (en) 2014-11-27
EP3003291A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
HK1213264A1 (zh) 经取代的苯化合物
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201591180A1 (ru) Составы ингибитора lfa-1
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]